Sign up to save your data!
Some tips to help get started:
Processing...
There are 746 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
746 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with platinum-refractory extensive stage small cell or stage IV non-small cell lung cancer previously treated with PD-1/PD-L1 inhibitors, evaluating autologous T cells engineered to express a GD2-directed CAR, IL-15 for enhanced persistence, and an inducible caspase 9 safety switch. Patients receive leukapheresis, ex vivo T cell modification, and a single infusion of this investigational CAR T cell therapy.
ClinicalTrials.gov ID: NCT05620342
HealthScout AI summary: Eligible patients are adults with advanced solid tumors harboring a KRAS G12D mutation, measurable disease, ECOG 0-1, and prior systemic chemotherapy. The trial evaluates oral LY3962673, a selective KRAS G12D inhibitor, as monotherapy and in combination with standard chemotherapies (including agents such as FOLFOX, FOLFIRI, and gemcitabine/nab-paclitaxel).
ClinicalTrials.gov ID: NCT06586515
HealthScout AI summary: This trial enrolls adults with locally advanced, recurrent, or metastatic non-small cell lung cancer (both non-squamous and squamous), whose tumors have cMET overexpression or MET aberrations, including patients previously treated with standard therapies and both EGFR mutation-positive and -negative subgroups. Patients receive MYTX-011, a cMET-directed antibody-drug conjugate delivering MMAE, with dose escalation and expansion in molecularly defined cohorts.
ClinicalTrials.gov ID: NCT05652868
HealthScout AI summary: This study enrolls adults with advanced, unresectable, or metastatic solid tumors—including MSS colorectal, head and neck, melanoma, and non-small cell lung cancers—who have progressed on or are intolerant to standard therapies, to receive SNS-101, a novel monoclonal antibody targeting VISTA for selective immunomodulation in the tumor microenvironment, as monotherapy or in combination with the anti-PD-1 antibody cemiplimab.
ClinicalTrials.gov ID: NCT05864144
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic solid tumors harboring HER2 aberrations (mutations, amplification, or overexpression) or EGFR exon 20 insertions who have progressed on standard therapies, and treats them with YH42946, an oral tyrosine kinase inhibitor targeting mutant HER2 and EGFR exon 20 insertions.
ClinicalTrials.gov ID: NCT06616766
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors linked to COX2-mediated immunosuppression who have exhausted standard therapies, including specific expansion cohorts for sarcoma, pancreatic cancer, NSCLC without driver mutations, microsatellite stable/low colorectal cancer, and head and neck squamous cell carcinoma. Patients receive OKN4395, an oral triple antagonist of EP2, EP4, and DP1 prostanoid receptors, as monotherapy or in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT06789172
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (including classical, atypical, exon 20 insertion, and resistance mutations) and/or HER2 kinase domain mutations who have received standard therapies, testing the investigational oral agent BH-30643, a mutant-selective OMNI-EGFR inhibitor targeting a broad spectrum of EGFR and HER2 mutations. Patients must have measurable disease, good performance status, and no significant comorbidities or prior ILD.
ClinicalTrials.gov ID: NCT06706076
HealthScout AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929
HealthScout AI summary: Adults with advanced unresectable or metastatic melanoma (non-uveal/mucosal), head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, or classical Hodgkin lymphoma who have progressed on prior PD-1/PD-L1 therapy are eligible to receive CTX-8371, an investigational bispecific antibody targeting PD-1 and PD-L1 designed to overcome checkpoint inhibitor resistance, as monotherapy.
ClinicalTrials.gov ID: NCT06150664
HealthScout AI summary: This trial enrolls adults with advanced or metastatic Claudin-1 positive squamous solid tumors (including SqNSCLC, HNSCC, ESCC, or CSCC) who are refractory or intolerant to standard therapies. Patients receive ALE.P02, a CLDN1-targeted antibody-drug conjugate that delivers a tubulin inhibitor selectively to CLDN1-positive tumor cells.
ClinicalTrials.gov ID: NCT06747585
